{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:57:02Z","timestamp":1793422622770,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ncl.2022.05.005","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:30:38Z","timestamp":1667176238000},"page":"141-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Chronic Migraine"],"prefix":"10.1016","volume":"41","author":[{"given":"Doris","family":"Kung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gage","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randolph","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ncl.2022.05.005_bib1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/head.12774","article-title":"Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study","volume":"56","author":"Dodick","year":"2016","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2022.05.005_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J\u00a0Headache Pain"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.005_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1474-4422(18)30360-0","article-title":"GBD 2016: still no improvement in the burden of Migraine","volume":"17","author":"Reuter","year":"2018","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.005_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review","volume":"30","author":"Natoli","year":"2009","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1016\/j.ncl.2022.05.005_bib5","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","article-title":"Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American migraine prevalence and Prevention Study","volume":"52","author":"Buse","year":"2012","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.005_bib6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","article-title":"Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study","volume":"48","author":"Bigal","year":"2008","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.005_bib7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol Clin"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.005_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1212\/WNL.0b013e31820d8af2","article-title":"Rates, Predictors, and consequences of remission from chronic migraine to episodic migraine","volume":"76","author":"Manack","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd Edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.005_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","article-title":"Chronic migraine: risk factors, mechanisms and treatment","volume":"12","author":"May","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.005_bib11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/head.13459","article-title":"Migraine progression: a systematic review","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.005_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3949\/ccjm.86a.19009","article-title":"Seeds for success: lifestyle Management in Migraine","volume":"86","author":"Robblee","year":"2019","journal-title":"Cleve Clin J Med"},{"issue":"7","key":"10.1016\/j.ncl.2022.05.005_bib13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","article-title":"Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine","volume":"84","author":"Lipton","year":"2015","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.ncl.2022.05.005_bib14","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1001\/jama.284.20.2599","article-title":"Stratified care vs step care strategies for migraine: the disability in strategies of care (DISC) study: a randomized trial","volume":"284","author":"Lipton","year":"2000","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ncl.2022.05.005_bib15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of Migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"issue":"24","key":"10.1016\/j.ncl.2022.05.005_bib16","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.005_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jcph.1543","article-title":"Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study","volume":"60","author":"Wilbraham","year":"2019","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.005_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0333102420920006","article-title":"Evaluation of ly573144 (lasmiditan) in a preclinical model of medication overuse headache","volume":"40","author":"Rau","year":"2020","journal-title":"Cephalalgia"},{"issue":"19","key":"10.1016\/j.ncl.2022.05.005_bib19","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of Migraine","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"issue":"10200","key":"10.1016\/j.ncl.2022.05.005_bib20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of Migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"The Lancet"},{"issue":"23","key":"10.1016\/j.ncl.2022.05.005_bib21","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of Migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"18 Supplement","key":"10.1016\/j.ncl.2022.05.005_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1212\/WNL.98.18_supplement.167","article-title":"Within-person analysis of ubrogepant treatment of mild versus moderate-severe headache pain during a phase 3 long-term safety extension trial (S31.006)","volume":"98","author":"Lipton","year":"2022","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.005_bib23","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/head.13930","article-title":"Safety of Rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for Migraine. Headache","volume":"60","author":"Berman","year":"2020","journal-title":"J\u00a0Head Face Pain"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.005_bib24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.25831","article-title":"Anti-migraine calcitonin gene\u2013related peptide receptor antagonists worsen cerebral ischemic outcome in mice","volume":"88","author":"Mulder","year":"2020","journal-title":"Ann Neurol"},{"issue":"4\u20135","key":"10.1016\/j.ncl.2022.05.005_bib25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/03331024211047454","article-title":"TOP-PRO Study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine","volume":"42","author":"Chowdhury","year":"2022","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.005_bib26","doi-asserted-by":"crossref","first-page":"e0212785","DOI":"10.1371\/journal.pone.0212785","article-title":"Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis","volume":"14","author":"Jackson","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.005_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/ane.12626","article-title":"Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial","volume":"135","author":"Lai","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib28","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/s41598-021-83508-2","article-title":"Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study","volume":"11","author":"S\u00e1nchez-Rodr\u00edguez","year":"2021","journal-title":"Scientific Rep"},{"key":"10.1016\/j.ncl.2022.05.005_bib29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/CON.0000000000000199","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein","year":"2015","journal-title":"Continuum"},{"issue":"7","key":"10.1016\/j.ncl.2022.05.005_bib30","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The american headache society consensus statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"issue":"mar24 5","key":"10.1016\/j.ncl.2022.05.005_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1416","article-title":"Chronic migraine","volume":"348","author":"Schwedt","year":"2014","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.005_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nrneurol.2012.13","article-title":"Chronic migraine--classification, characteristics and Treatment","volume":"8","author":"Diener","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.005_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2022.05.005_bib34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Diener","year":"2007","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.ncl.2022.05.005_bib35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/CON.0000000000000957","article-title":"Preventive migraine treatment","volume":"27","author":"Burch","year":"2021","journal-title":"Continuum"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2022.05.005_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10072-010-0268-7","article-title":"Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials","volume":"31","author":"D\u2019Amico","year":"2010","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ncl.2022.05.005_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10194-008-0002-5","article-title":"The effect of sodium valproate on chronic daily headache and its subgroups","volume":"9","author":"Yurekli","year":"2008","journal-title":"J\u00a0Headache Pain"},{"issue":"12","key":"10.1016\/j.ncl.2022.05.005_bib38","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/01.WNL.0000100121.58594.11","article-title":"Gabapentin in the prophylaxis of chronic daily headache","volume":"61","author":"Spira","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/WNF.0b013e3181bf1dbe","article-title":"Pregabalin in the treatment of chronic migraine: an open-label study","volume":"33","author":"Calandre","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2022.05.005_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1129-2377-14-S1-P215","article-title":"Zonisamide is effective in the preventive therapy of chronic migraine: doc 551","volume":"14","author":"Belvis","year":"2013","journal-title":"J\u00a0Headache Pain"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.005_bib41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1526-4610.2010.01842.x","article-title":"Zonisamide for migraine prophylaxis in topiramate-intolerant patients: An observational study","volume":"51","author":"Villani","year":"2011","journal-title":"Headache"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.005_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0b013e318170577f","article-title":"Zonisamide for migraine prophylaxis in patients refractory to topiramate","volume":"32","author":"Bermejo","year":"2009","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/head.12480","article-title":"The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension","volume":"55","author":"Jion","year":"2015","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","article-title":"Amitriptyline in the prophylactic treatment of migraine and chronic daily headache","volume":"51","author":"Couch","year":"2011","journal-title":"Headache"},{"issue":"10","key":"10.1016\/j.ncl.2022.05.005_bib45","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/head.12987","article-title":"Amitriptyline dose and treatment outcomes in specialty headache practice: a retrospective cohort study","volume":"56","author":"Doyle Strauss","year":"2016","journal-title":"Headache"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.005_bib46","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.4088\/JCP.v69n0912","article-title":"An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache","volume":"69","author":"Volpe","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.005_bib47","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/head.12205","article-title":"Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study","volume":"53","author":"Young","year":"2013","journal-title":"Headache"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.005_bib48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11916-019-0823-8","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults","volume":"23","author":"Dorosch","year":"2019","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.005_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11940-019-0559-0","article-title":"Other preventive anti-migraine treatments: ACE inhibitors, ARBS, calcium channel blockers, serotonin antagonists, and NMDA receptor antagonists","volume":"21","author":"Rau","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2022.05.005_bib50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0333102413515348","article-title":"A\u00a0comparative study of Candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study","volume":"34","author":"Stovner","year":"2013","journal-title":"Cephalalgia"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.005_bib51","first-page":"3243","article-title":"Candesartan in migraine prevention: results from a retrospective real-world study","volume":"267","author":"Messina","year":"2020","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib52","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/2193-1801-2-479","article-title":"Atenolol in the Prophylaxis of Chronic Migraine: a 3-Month Open-Label Study","volume":"2","author":"Edvardsson","year":"2013","journal-title":"SpringerPlus"},{"issue":"6","key":"10.1016\/j.ncl.2022.05.005_bib53","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1526-4610.2002.02126.x","article-title":"Olanzapine in the treatment of refractory migraine and chronic daily headache","volume":"42","author":"Silberstein","year":"2002","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.ncl.2022.05.005_bib54","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1526-4610.2002.02122.x","article-title":"Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study","volume":"42","author":"Saper","year":"2002","journal-title":"Headache"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.005_bib55","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1177\/1060028014548872","article-title":"Memantine for the prevention of primary headache disorders","volume":"48","author":"Huang","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.005_bib56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2B\/3 trial","volume":"19","author":"Goadsby","year":"2020","journal-title":"Lancet Neurol"},{"issue":"17","key":"10.1016\/j.ncl.2022.05.005_bib58","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.ncl.2022.05.005_bib59","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in Migraine: new drugs, new hope?","volume":"20","author":"Do","year":"2019","journal-title":"J\u00a0Headache Pain"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0333102419894559","article-title":"The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response","volume":"40","author":"Brandes","year":"2019","journal-title":"Cephalalgia"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.005_bib62","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/0333102419854082","article-title":"Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine","volume":"39","author":"Ashina","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2022.05.005_bib63","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/head.13379","article-title":"History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from Translational Research to treatment","volume":"58","author":"Tepper","year":"2018","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.005_bib64","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/head.13596","article-title":"Raynaud's phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists","volume":"59","author":"Evans","year":"2019","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.005_bib65","doi-asserted-by":"crossref","first-page":"e217934","DOI":"10.1001\/jamanetworkopen.2021.7934","article-title":"Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with raynaud phenomenon","volume":"4","author":"Breen","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib66","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt","year":"2018","journal-title":"J\u00a0Headache Pain"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1212\/CON.0000000000001070","article-title":"Headache in pregnancy and lactation","volume":"28","author":"Rayhill","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"12","key":"10.1016\/j.ncl.2022.05.005_bib68","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/14740338.2021.1942839","article-title":"Safety and tolerability of preventive treatment options for chronic migraine","volume":"20","author":"Tinsley","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"10.1016\/j.ncl.2022.05.005_bib69","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2022.05.005_bib70","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/jnnp-2020-324674","article-title":"Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects","volume":"92","author":"Ray","year":"2021","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.005_bib71","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: a randomized phase 2B clinical trial","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.ncl.2022.05.005_bib72","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"Arise: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"issue":"22","key":"10.1016\/j.ncl.2022.05.005_bib73","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A\u00a0controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ncl.2022.05.005_bib74","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.005_bib75","first-page":"1052","article-title":"Vascular safety of erenumab for migraine prevention","volume":"94","author":"Kudrow","year":"2019","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.ncl.2022.05.005_bib76","doi-asserted-by":"crossref","first-page":"e2250","DOI":"10.1212\/WNL.0000000000007452","article-title":"Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study","volume":"92","author":"Lipton","year":"2019","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.ncl.2022.05.005_bib77","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ncl.2022.05.005_bib78","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ncl.2022.05.005_bib79","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.005_bib80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","article-title":"Effect of different doses of galcanezumab vs placebo for episodic migraine prevention","volume":"75","author":"Skljarevski","year":"2018","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.005_bib81","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.005_bib82","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40265-018-0894-6","article-title":"A\u00a0review in the prevention of chronic migraine","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ncl.2022.05.005_bib83","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Diener","year":"2010","journal-title":"Headache"},{"issue":"9","key":"10.1016\/j.ncl.2022.05.005_bib84","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Percent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein","year":"2015","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.005_bib85","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.ncl.2022.05.005_bib86","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/archderm.138.4.510","article-title":"Pain associated with injection of botulinum a exotoxin reconstituted using isotonic sodium chloride with and without preservative","volume":"138","author":"Alam","year":"2002","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxicon.2011.04.019","article-title":"Flu-like symptoms following botulinum toxin therapy","volume":"58","author":"Baizabal-Carvallo","year":"2011","journal-title":"Toxicon"},{"issue":"13","key":"10.1016\/j.ncl.2022.05.005_bib88","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/WNL.0b013e31824d5846","article-title":"Chronic Migraine Treatment Trial Research Group. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33425\/2639-846X.1037","article-title":"Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study","volume":"4","author":"Boudreau","year":"2020","journal-title":"Anesth Pain Res"},{"issue":"1","key":"10.1016\/j.ncl.2022.05.005_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","article-title":"Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis","volume":"35","author":"Armanious","year":"2021","journal-title":"J\u00a0Pain Palliat Care Pharmacother"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.005_bib91","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/pm\/pnab093","article-title":"Efficacy and tolerability of calcitonin gene-related peptide targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine","volume":"22","author":"Cohen","year":"2021","journal-title":"Pain Med"},{"issue":"2","key":"10.1016\/j.ncl.2022.05.005_bib92","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","article-title":"Real-World evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review","volume":"10","author":"Blumenfeld","year":"2021","journal-title":"Pain Ther"},{"issue":"18 supplement","key":"10.1016\/j.ncl.2022.05.005_bib93","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/WNL.98.18_supplement.14","article-title":"Combined Prophylactic treatment of chronic migraine with OnabotulinumtoxinA and Anti-CGRP monoclonal antibodies (P14-2.001)","volume":"98","author":"Blazek","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2022.05.005_bib94","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/WNL.0000000000002918","article-title":"Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study","volume":"87","author":"Silberstein","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2022.05.005_bib95","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11916-021-00988-7","article-title":"Update of neuromodulation in chronic migraine","volume":"25","author":"Yuan","year":"2021","journal-title":"Curr Pain Headache Rep"},{"issue":"12","key":"10.1016\/j.ncl.2022.05.005_bib96","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S1474-4422(07)70272-7","article-title":"Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial","volume":"6","author":"Diener","year":"2007","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2022.05.005_bib97","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/head.13630","article-title":"Prognosis following discontinuation of OnabotulinumA Therapy in \"Super-responding\" Chronic Migraine Patients","volume":"59","author":"Ching","year":"2019","journal-title":"Headache"},{"issue":"4\u20135","key":"10.1016\/j.ncl.2022.05.005_bib98","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/03331024211046617","article-title":"Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study","volume":"42","author":"Raffaelli","year":"2022","journal-title":"Cephalalgia"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861922000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861922000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:22:14Z","timestamp":1760005334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861922000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0733861922000457"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2022.05.005","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Migraine","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2022.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}